GoAI
Get started
Equillium, Inc. logo

Equillium, Inc.

EQ

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.31

+$0.04 · +1.76%

Aug 21, 4:00 PM ET

EQ company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

33

Expensive

Momentum

88

Strong Up

Sentiment

75

Bullish

Risk resilience

41

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Bruce D. Steel
Listed since
Oct 12, 2018
Employees
14

Market position

Day range

Current $2.31

52-week range

Current $2.31

Open
$2.30
Previous close
$2.27
Volume
557.35K
0.79× average
Average volume
705.63K
Average daily volume
Market cap
146.05M USD
Beta
1.81
Market reference 1
50-day average
$2.6044
-11.30% below average
200-day average
$1.9285
+19.78% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
112.86M USD
P/E (TTM)
-9.01×
P/B (TTM)
4.61×
P/S (TTM)
0×
EV / EBITDA
-5.06×
Earnings yield
-15.73%
Free cash flow yield
-16.01%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-78.32%
Return on assets
-70.24%
Return on invested capital
-83.32%

Financial health

Debt / equity
0.01×
Current ratio
10.32×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends150%-49%-247%-446%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Operating margin, FY2022: -393.91%Operating margin, FY2023: -40.24%Operating margin, FY2024: -20.12%Net margin, FY2022: -396.14%Net margin, FY2023: -36.96%Net margin, FY2024: -19.63%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Operating margin FY2022 -393.91%. Operating margin FY2023 -40.24%. Operating margin FY2024 -20.12%. Net margin FY2022 -396.14%. Net margin FY2023 -36.96%. Net margin FY2024 -19.63%.

Income trends

Revenue

41.1M USD+13.89%

Operating income

−23.63M USD-185.81%

Net income

−22.4M USD-177.65%
Income trends across reported periods51.45M USD10.04M USD−31.37M USD−72.78M USDRevenue, FY2022: 15.76M USDRevenue, FY2023: 36.08M USDRevenue, FY2024: 41.1M USDOperating income, FY2021: −37.79M USDOperating income, FY2022: −62.08M USDOperating income, FY2023: −14.52M USDOperating income, FY2024: −8.27M USDOperating income, FY2025: −23.63M USDNet income, FY2021: −38.98M USDNet income, FY2022: −62.43M USDNet income, FY2023: −13.34M USDNet income, FY2024: −8.07M USDNet income, FY2025: −22.4M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2022 15.76M USD. Revenue FY2023 36.08M USD. Revenue FY2024 41.1M USD. Operating income FY2021 −37.79M USD. Operating income FY2022 −62.08M USD. Operating income FY2023 −14.52M USD. Operating income FY2024 −8.27M USD. Operating income FY2025 −23.63M USD. Net income FY2021 −38.98M USD. Net income FY2022 −62.43M USD. Net income FY2023 −13.34M USD. Net income FY2024 −8.07M USD. Net income FY2025 −22.4M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue—41.1M USD36.08M USD15.76M USD—
Cost of goods sold116K USD————
Gross profit−116K USD41.1M USD36.08M USD15.76M USD—
Research and development12.84M USD37.43M USD37.04M USD37.55M USD26.38M USD
Selling, general, and administrative10.79M USD11.94M USD13.57M USD17.24M USD11.41M USD
Operating expenses23.63M USD49.36M USD50.61M USD77.84M USD37.79M USD
Interest income833K USD1.38M USD2.33M USD420K USD57K USD
Interest expense——491K USD1.05M USD1.07M USD
Depreciation and amortization116K USD137K USD126K USD118K USD72K USD
Operating income−23.63M USD−8.27M USD−14.52M USD−62.08M USD−37.79M USD
Net income−22.4M USD−8.07M USD−13.34M USD−62.43M USD−38.98M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+36.63%
11 comparable reports
Latest EPS result
-0.04
Estimate -0.05 · Beat by 25.93%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.03-0.12-0.2-0.28Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -0.16, estimate -0.22, surprise +27.27%, Beat. Q2 2025, reported May 14, 2025: actual -0.24, estimate -0.23, surprise -4.35%, Miss. Q3 2025, reported Aug 14, 2025: actual -0.16, estimate -0.14, surprise -14.29%, Miss. Q4 2025, reported Nov 13, 2025: actual -0.06, estimate -0.14, surprise +57.14%, Beat. Q1 2026, reported Mar 25, 2026: actual -0.04, estimate -0.07, surprise +42.86%, Beat. Q2 2026, reported May 13, 2026: actual -0.06, estimate -0.04, surprise -50.00%, Miss. Q3 2026, reported Aug 13, 2026: actual -0.04, estimate -0.054, surprise +25.93%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.05, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates22.76M16.42M10.08M3.73MQ1 '24BeatQ2 '24BeatQ3 '24MissQ4 '24BeatQ1 '25No estimate
Q1 2024, reported Mar 25, 2024: actual 9.21M USD, estimate 8M USD, surprise +15.14%, Beat. Q2 2024, reported May 9, 2024: actual 10.69M USD, estimate 9M USD, surprise +18.77%, Beat. Q3 2024, reported Aug 8, 2024: actual 13.85M USD, estimate 21.4M USD, surprise -35.27%, Miss. Q4 2024, reported Nov 13, 2024: actual 12.16M USD, estimate 11.55M USD, surprise +5.29%, Beat. Q1 2025, reported Mar 27, 2025: actual 4.39M USD, estimate —, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$6.25

170.56% upside
Past 12 months12-month forecastHigh $7.00Average $6.25Low $5.00

Rating distribution

12 ratings
Strong buy00%
Buy1192%
Hold18%
Sell00%
Strong sell00%

EQ news

globenewswire.com

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expected to fund operations into 2029 LA JOLLA,…

Read source
defenseworld.net

Equillium, Inc. (NASDAQ:EQ) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Equillium, Inc. (NASDAQ: EQ - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated…

Read source
accessnewswire.com

EQ Works Expands Multi-Year Partnership with Leading Canadian Publisher to Include SaaS License for ClearLake

Three-year renewal follows early campaign results that delivered up to 40% increases in average order value and nearly double the conversion rates using ClearLake TORONTO, ON / ACCESS Newswire / June 18, 2026 / EQ Inc.…

Read source
globenewswire.com

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June…

Read source
seekingalpha.com

Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript

Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript

Read source
marketbeat.com

Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1

Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined new preclinical data during a company webinar focused on the relationship between the aryl hydrocarbon receptor, or AhR, and miR-124, a microRNA…

Read source

EQ peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding EQ

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
3.08M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
821.41K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
354.39K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
105.75K
Weight
—
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%
Invesco NASDAQ Future Gen 200 ETF logoInvesco NASDAQ Future Gen 200 ETFQQQS
Market value
87.53K
Weight
0.39%
AUM
22.98M USD
Expense ratio
0.20%
Price / 1D
$45.0826+1.10%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
17.41K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
17.4K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%

Continue in GoAI

Research EQ

research.disclaimer